Morgan Stanley: Maintains COSCO SHIPPING Energy Transportation (01138) target price at HK$26, reiterates "Overweight" rating.
Company management expects that most of the sharply rising freight rates in September will be reflected in fourth-quarter results, while disruptions in the Strait of Hormuz may prove more prolonged than expected, supporting a continued bull market in tanker shipping.
Morgan Stanley released a research report reiterating its "Overweight" rating on COSCO SHIPPING Energy Transportation (01138), maintaining the target price at HK$26. The bank expects that, benefiting from higher freight rates and improved utilization, COSCO SHIPPING Energy Transportation's earnings in the third quarter of this year will improve quarter-on-quarter.
Management believes that the current sharp rise in VLCC freight rates mainly reflects a significant tightening of effective capacity, in contrast to increasing cargo demand. Recently, the daily charter rate for three-year VLCC time charter contracts in the market reached US$100,000, which management believes provides a stronger medium-term pricing signal. Company management expects that most of the sharply risen freight rates in September will be reflected in fourth-quarter results, and that disruptions in the Strait of Hormuz may last longer than expected, supporting a continued bull market in tanker shipping.
COSCO SHIPPING Energy Transportation holds orders for 6 VLCCs and has 6 bareboat-chartered VLCCs scheduled for delivery in 2027 to 2028. Despite high spot freight rates, management remains cautious about fleet expansion through chartering.
Related Articles

General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.

EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.

Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint
General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.

EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.

Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint

RECOMMEND





